Drug Risks And Benefits Should Be Quantified For Public, Pfizer Exec Says
This article was originally published in The Pink Sheet Daily
Industry will collaborate with FDA on ways to communicate risk/benefit information to patients, physicians and lawmakers, Pfizer Senior VP Corr says.
You may also be interested in...
Evidence-based standards currently applied to risk should be applied to benefit, the FDAer adds.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.